Major Improvements in Treating Hodgkin's Disease

Hodgkin lymphoma (also called Hodgkin’s disease) is one of the most common cancers to affect young adults under 40. Just thirty years ago, the survival rate was less than one third.

Now, Hodgkin lymphoma is considered one of the most curable cancers due to rapid and successful advancements in treatments and diagnosis.

Technical advancements are partly responsible for the improvements in the methods for diagnosing Hodgkin lymphoma. In the past, the protocol for diagnosing Hodgkin’s Disease required X-rays, bone marrow biopsies, and surgical removal of the spleen. Now, physicians use noninvasive and less toxic positron emission topography (PET) scans to create a 3D image of the body. They inject glucose into the patient’s veins, which attracts cancerous cells and shows up on the PET scan.

Chemotherapy has also gone through a major transformation since the 1980s. It is now safer and more effective to use in early stages of cancer and new medications can help prevent chemotherapy-related side effects such as nausea, vomiting, hair loss, and infection.

Even in advanced stages, Hodgkin lymphoma is highly curable with chemotherapy.

In the early stages, targeted radiation therapy is the most common treatment. Even when chemotherapy is not effective, stem cell transplants have proven effective to eradicate cancer.

Due to the new technological and medical improvements in treatment and diagnosis, the five-year survival rate for Hodgkin’s disease is now 90%. This is great news for the many young patients with blood cancer who benefit from these new advancements.

Source: UT San Diego.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap